Quidel closes $680M acquisition of Alere assets
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Quidel Corp. completed the $680 million acquisition of Alere's Triage MeterPro cardiovascular and toxicology business, as well as the B-type Naturietic Peptide assay business.
The purchase price included $400 million in cash for the Triage business and a $280 million in deferred consideration for the assay business.
The Triage assets also include the facilities in San Diego.
